Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions.
about
Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysisGenetics of Common Antipsychotic-Induced Adverse EffectsCOMT val158met moderation of dopaminergic drug effects on cognitive function: a critical reviewThe role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humansBDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysisPharmacogenetics of antipsychotics.Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disordersPharmacogenetics and antipsychotics: therapeutic efficacy and side effects predictionPersonalized medicine in psychiatry: problems and promises.Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder.PharmGKB summary: dopamine receptor D2Genomewide association study of movement-related adverse antipsychotic effects.Multilocus genetic profile for dopamine signaling predicts ventral striatum reactivity.The promise and reality of pharmacogenetics in psychiatryPharmacogenetics of antipsychotic-induced side effectsPharmGKB summary: very important pharmacogene information for CYP1A2.Redox processes in neurodegenerative disease involving reactive oxygen speciesLikelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations.An update on tardive dyskinesia: from phenomenology to treatmentPharmacogenetics in psychiatry: are we ready for widespread clinical use?Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.The role of pharmacogenetics in treating central nervous system disorders.Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations.A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trialTardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations.Genetics of antipsychotic-induced side effects and agranulocytosis.Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia.Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis.Movement disorders and psychosis, a complex marriage.Identification and management of tardive dyskinesia: A case series and literature review.Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder.Therapeutic Perspective on Tardive Syndrome with Special Reference to Deep Brain Stimulation.Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis.The catechol-O-methyl-transferase gene in tardive dyskinesia.Support for association of HSPG2 with tardive dyskinesia in Caucasian populations.There is no evidence for an association between the serotonin receptor 3A gene C178T polymorphism and tardive dyskinesia in Korean schizophrenia patients.Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers.Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.Possible association between DBH 19 bp insertion/deletion polymorphism and clinical symptoms in schizophrenia with tardive dyskinesia.
P2860
Q24600775-EFBCF791-C3E2-459B-A5D2-BCCCBFC4DD33Q28072893-EDD138B7-9B47-4FCD-A226-F79230420F47Q28074860-F3021C23-67C1-451F-B8B4-643D586D4C99Q28543192-4E839348-5028-43AA-B3B4-C71C75D22F49Q33566832-C0EF503A-0509-4164-8C8D-C781DF0AD58DQ33836837-10661D1B-F843-424B-93AC-F4D4FEBE3126Q34391577-61D430ED-2EB0-46C7-A5E8-7D5F6D31EC13Q34676533-C0222EB7-7CC7-40CF-8499-F4DB17EC9B44Q34726454-2BB21FEF-C090-41AD-B1F8-FF6EFDA6B756Q34871885-E8B6A112-F8DE-4C07-B194-7EE123D077B9Q34970259-E7616B9B-04E9-4853-B1AD-1822F4DB6D4FQ35010386-90C0CE82-9262-4E35-BB4E-E73D4522ED08Q35158208-096E58A9-264D-46C1-B696-FAFCB4685AECQ35226451-389596DB-085D-4AD8-AE2A-414B6B8BABB9Q35237129-B6B0FC76-3E0A-46C7-A54A-45D397694BB9Q35940452-0442A109-E445-4B9F-BBC1-C39E249B34D2Q36460613-BD0C39A4-75FE-4399-A858-27164DDE0B33Q36806137-D12D04C0-FFC1-4E64-9C2A-FEFC04D62280Q37006021-3D529E6B-3F13-483C-8950-0FFD00A01A88Q37076472-F0F982D2-55C1-4D63-BBB1-CECC397394BEQ37264543-4EA1C31A-FB43-429B-AC01-0094F3CBC1D8Q37292132-4FA74FE8-11D4-40B8-996C-CFF0118A4791Q37344782-C9A2EB5E-83BD-4407-8F28-4F819AB0691AQ37489656-A48EE6F0-1095-4EC0-9DA9-9D2E49EF646EQ37707292-423B3EC3-6895-469D-9CAF-A2FD65D2D2B3Q37845227-A2E5A584-5225-4780-91A8-6681861D7C0BQ37960512-DF41E593-74B1-4319-8855-387D59DA3D35Q38032249-DC0FCDC6-0C05-44F0-88DD-0B0410069F5BQ38332389-B8E1B2FD-026E-49E2-847C-627AFDD9A346Q38555637-2971318E-7597-4903-99F0-E8B489976BB4Q38661378-D82722CD-4EF6-4C5F-95B9-1711EB65BE9DQ39084564-E3BEEBE4-0E68-4969-8DA8-093A5AEA088FQ42750226-69066973-A7CA-4FB7-9D1F-946899EC327DQ43002336-3147025F-088A-4A51-86F7-0A1475585181Q44208517-BCF6B174-1B0D-4727-8779-36FEA6206C47Q44820338-D41C0333-44FF-4C3D-9C76-7E245E27003EQ45007058-63EF22B4-4B9C-4B32-90D8-218F0C590FCCQ47998134-E6B77517-EFF3-4A91-BD8E-119830DFE8A2Q48006592-AE95E719-84BF-4BAD-8242-0ACEFC7721EDQ50616840-8E48F653-FA6A-41CC-B5A8-B27D338FBECD
P2860
Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Antipsychotic-induced tardive ...... pharmacogenetic interactions.
@en
type
label
Antipsychotic-induced tardive ...... pharmacogenetic interactions.
@en
prefLabel
Antipsychotic-induced tardive ...... pharmacogenetic interactions.
@en
P2093
P2860
P356
P1433
P1476
Antipsychotic-induced tardive ...... pharmacogenetic interactions.
@en
P2093
P N van Harten
P R Bakker
P2860
P2888
P304
P356
10.1038/SJ.MP.4002142
P407
P577
2008-01-08T00:00:00Z